In mouse model studies, Asxl1 along with Tet methylcytosine dioxygenase 2 (Tet2) mutation initiated MDS-like hematopoietic impairment [92,96], and concurrent oncogenic mutations such as Kras and Nf1 accelerated the development of myeloid leukemia [97]. The gene discussed is TET2; the disease is myelodysplastic syndrome.